VAmgen collaboration; BeiGene has China commercial rights. MEnsem collaboration; BeiGene has global rights. QDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. hLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 2Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 4Amgen collaboration; BeiGene has development and commercialization rights in China. BIn combination with Zanubrutinib. ^May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.
Welcome to BeiMedPlus
BeiGene’s Medical Affairs website for healthcare professionals.
BeiMedPlus is intended for health care professionals in the United States for the purpose of scientific exchange. This site contains educational resources and information relating to BeiGene medicines, therapeutic areas of interest, congress materials, and publications. This site may include information on products or indications under investigation that are currently not approved in the United States. BeiGene does not recommend the use of its products other than as described in the approved prescribing information. This site does not contain medical advice and does not replace independent medical judgment.
Please visit beigene.com for more information.